Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...
Travere Therapeutics, Inc.: Travere Therapeutics to Submit sNDA for FILSPARI (sparsentan) in FSGS
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated ...
pharmaphorum21h
A history of AstraZeneca
It is based on an adenoviral vector based on a weakened version of the adenovirus that causes a common cold-line illness in chimpanzees, containing the genetic material of the SARS-CoV-2 spike ...
Space Coast launch schedule
The Space Coast set a new record in 2024 with 93 launches from all providers, building off the 72 orbital missions flown in 2023. With SpaceX’s continued pace, more launches from United Launch ...
The Lancet18h
Breaking the silence: MASLD and the scarcity of data on the Roma population
Non-communicable diseases rank among the most serious global health challenges of the 21st century due to their high prevalence and substantial socioeconomic and health-care impact. According to WHO, ...